Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;608(7922):271-272.
doi: 10.1038/d41586-022-01948-w.

A short burst of reward curbs the addictiveness of ketamine

Comment

A short burst of reward curbs the addictiveness of ketamine

Rianne Campbell et al. Nature. 2022 Aug.

Abstract

An analysis of ketamine and cocaine use in mice reveals that the drugs trigger release of the neurotransmitter dopamine through different mechanisms, and indicates that the risk of addiction to ketamine is low.

Keywords: Depression; Neuroscience.

PubMed Disclaimer

Figures

Figure 1 |
Figure 1 |. The effects of ketamine on dopamine release.
a, GABAergic neurons in the brain’s ventral tegmental area (VTA) are stimulated by binding of the neurotransmitter glutamate to NMDA receptor proteins. These neurons release the neurotransmitter GABA, which inhibits the activity of dopamine neurons that project to a reward centre called the nucleus accumbens (NAc). b, Ketamine binds to NMDA receptors to inhibit their activation. Simmler et al. show that this leads to activation of the dopamine neurons, triggering a short burst of dopamine release in the NAc. The release is rapidly quashed when dopamine binds to the D2-type receptor (D2R) protein on the dopamine neurons, inhibiting their activity. This mechanism of action differs from the pathways through which cocaine triggers sustained dopamine release (not shown), which might explain why ketamine is not highly addictive.

Comment on

References

    1. Krystal JH, Abdallah CG, Sanacora G, Charney DS & Duman RS Neuron 101, 774–778 (2019). - PMC - PubMed
    1. Morgan CJA, Curran HV & the Independent Scientific Committee on Drugs (ISCD). Addiction 107, 27–38 (2012). - PubMed
    1. Simmler LD et al. Nature 608, 368–373 (2022). - PubMed
    1. Dayan P. & Niv Y. Curr. Opin. Neurobiol. 18, 185–196 (2008). - PubMed
    1. Saunders BT, Richard JM, Margolis EB & Janak PH Nature Neurosci. 21, 1072–1083 (2018). - PMC - PubMed